Omeros Corporation (OMER)
Omeros Corporation Revenue Growth: 17.11%
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
OMER Revenue Growth Rankings
| Overall | 72nd percentile | 1204 of 4364 |
| Sector | 67th percentile | 150 of 456 in Healthcare |
| Industry | 57th percentile | 54 of 126 in Biotechnology |
OMER Revenue Growth Range, Past 5 Years
| Minimum | -42.53% | Sep 2010 |
| Maximum | 288.6% | Sep 2011 |
| Average | 109.4% |
About Revenue Growth
Revenue growth illustrates sales increases/decreases over time. It is used to measure how fast a business is expanding. More valuable than a snapshot of revenue, revenue growth helps investors identify trends in order to gauge revenue growth over time.
If a company generated $75 billion in revenue during 2008 and $100 billion in revenue during 2009, the company experienced roughly a ($100 billion/$75 billion)-1 = %33 increase in revenue.
Learn More
You may also be interested in these OMER related companies
OMER News
Omeros Announces Enrollment in Second Phase 3 Clinical Trial Evaluating OMS302
Apr 10, 7:06AM Benzinga
Apr 10, 7:06AM Benzinga
Omeros (OMER) Initiates Patient Enrollment for Second Phase 3 Trial of OMS302
Apr 10, 7:05AM Street Insider
Apr 10, 7:05AM Street Insider
Omeros Reports Allowance of Additional Patent for Ophthalmology Product OMS302
Mar 29, 7:01AM Benzinga
Mar 29, 7:01AM Benzinga
$OMER forms bullish "Flag" chart pattern. http://stks.co/37vO
about 63 days ago by RecogniaEvents
about 63 days ago by RecogniaEvents
Omeros Corporation Reports Fourth Quarter and Year-End 2011 Financial Results
Mar 15, 5:42PM PR Newswire
Mar 15, 5:42PM PR Newswire
$OMER surge yest could mean a thrust to the upside, maybe 12 1/2 –13 short-term. $EDAC took out multi-year high. http://stks.co/2r2D
about 77 days ago by thetechtrader
about 77 days ago by thetechtrader
$OMER moves up after being upgraded to Buy at Canaccord, impressive efficacy data from OMS302 Phase 3 trial. Price target to $13 from $5.
about 78 days ago by MilionCapital
about 78 days ago by MilionCapital
UPDATE - Canaccord Genuity Upgraded Omeros Corp. (OMER) to Buy; Impressive Efficacy Data From First OMS302 Phase 3 Trial
Mar 14, 8:45AM Street Insider
Mar 14, 8:45AM Street Insider
Wedbush Reiterates an 'Outperform' on Omeros Corp. (OMER); Hits Primary and Secondary Endpoints
Mar 13, 1:16PM Street Insider
Mar 13, 1:16PM Street Insider
Deutsche Bank Upgrades Omeros Corp. (OMER) to Buy; Strong Phase 3 Data in OMS302
Mar 13, 9:46AM Street Insider
Mar 13, 9:46AM Street Insider
Omeros (OMER) Reports Statistically Significant Data from OMS302 Phase 3
Mar 13, 7:12AM Street Insider
Mar 13, 7:12AM Street Insider
Anyone know when $OMER reports? I am guessing after the bell at this point.
about 80 days ago by mkarias1
about 80 days ago by mkarias1
Omeros to Present at the Cowen and Company 32nd Annual Health Care Conference
Mar 01, 7:00AM PR Newswire
Mar 01, 7:00AM PR Newswire
Adding Six More, Omeros Now Has a Total of 33 Unlocked Orphan GPCRs in its Portfolio
Feb 29, 7:00AM PR Newswire
Feb 29, 7:00AM PR Newswire
Omeros (OMER) to Revise Expectations for OMS302; May Expand Indication
Feb 07, 7:14AM Street Insider
Feb 07, 7:14AM Street Insider
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| OMER | 10.00 | +0.01 | +0.10% | 224.08M |
| OME | 6.55 | -0.06 | -0.91% | 129.49M |
| OMCL | 13.28 | -0.28 | -2.06% | 454.12M |
| NWY | 3.53 | -0.01 | -0.28% | 219.23M |
| NWSA | 19.40 | -0.29 | -1.47% | 32.99B |
| NWS | 19.59 | -0.31 | -1.56% | 50.16B |
| NWPX | 21.01 | -0.89 | -4.06% | 204.76M |
| NWN | 45.93 | -0.45 | -0.97% | 1.243B |
| NWLI | 126.82 | -2.23 | -1.73% | 468.45M |
| NWL | 18.49 | -0.54 | -2.84% | 5.488B |
